Biocitech appoints new ceo

Jean-Francois Boussard becomes chief executive of French life science technology park on 1 April.

Jean-Francois Boussard will become chief executive of Biocitech, the French life science technology park in Paris, on 1 April. He replaces Jacques Lhomel, who is retiring to pursue personal projects.

Boussard joins Biocitech after a biotechnology career in academia and industry. From 1994, after six years as patents, licensing and legal director in a financial holding company, he became an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was ceo of Substrat, a consultancy specialising in enterprise creation and management, project management and technology transfer in the field of biotechnology.

Prior to Substrat, Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982-88. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz.

"I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park," said Boussard.

Biocitech provides offices, laboratories and technical and scientific services.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Manufacturing

Automate Reactex glass reactor systems easily with Hitec Zang

Labtex, backed by more than 20 years of expertise in specialist laboratory and process chemistry equipment, is bringing advanced automation to its REACTEX glass reactor systems through innovative solutions from Hitec Zang
Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

RION engages Lonza to scale manufacturing exosome based therapeutics

Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Manufacturing

Kindeva to showcase complex drug delivery expertise at CPHI 2025

Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
Subscribe now